Matt Miksic
Stock Analyst at Barclays
(4.03)
# 540
Out of 4,754 analysts
268
Total ratings
64.06%
Success rate
6.15%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Overweight | $60 → $53 | $20.78 | +155.05% | 6 | Feb 28, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $103 | $79.25 | +29.97% | 14 | Feb 24, 2025 | |
| BAX Baxter International | Reinstates: Overweight | $39 | $34.86 | +11.88% | 20 | Feb 20, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $88 → $90 | $71.39 | +26.07% | 28 | Feb 13, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $118 → $112 | $105.38 | +6.28% | 7 | Feb 10, 2025 | |
| SYK Stryker | Maintains: Overweight | $418 → $443 | $394.88 | +12.19% | 23 | Feb 10, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $111 → $118 | $104.87 | +12.52% | 16 | Feb 10, 2025 | |
| INMD InMode | Maintains: Overweight | $26 → $29 | $18.89 | +53.52% | 12 | Feb 5, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $159 → $166 | $167.28 | -0.77% | 11 | Jan 28, 2025 | |
| ABT Abbott Laboratories | Maintains: Overweight | $149 → $158 | $140.22 | +12.68% | 28 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $12.27 | +71.15% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $7.17 | +206.83% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $16 | $4.10 | +290.24% | 1 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $94.30 | +15.59% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $220 → $234 | $272.64 | -14.17% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $138 → $113 | $85.99 | +31.41% | 5 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $490 → $510 | $566.98 | -10.05% | 6 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $13.49 | +18.61% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $57 → $61 | $41.72 | +46.21% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $18 | $15.86 | +13.49% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $94.14 | +1.98% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $70.81 | +41.22% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $175.09 | +138.73% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $11.68 | +139.73% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $15.99 | +319.01% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $9.33 | +5,044.69% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $22.45 | +287.61% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $5.41 | +362.11% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $8.30 | +8.43% | 1 | Dec 12, 2016 |
Tandem Diabetes Care
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $53
Current: $20.78
Upside: +155.05%
Globus Medical
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $79.25
Upside: +29.97%
Baxter International
Feb 20, 2025
Reinstates: Overweight
Price Target: $39
Current: $34.86
Upside: +11.88%
Edwards Lifesciences
Feb 13, 2025
Maintains: Overweight
Price Target: $88 → $90
Current: $71.39
Upside: +26.07%
Zimmer Biomet Holdings
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $105.38
Upside: +6.28%
Stryker
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $394.88
Upside: +12.19%
Boston Scientific
Feb 10, 2025
Maintains: Overweight
Price Target: $111 → $118
Current: $104.87
Upside: +12.52%
InMode
Feb 5, 2025
Maintains: Overweight
Price Target: $26 → $29
Current: $18.89
Upside: +53.52%
Johnson & Johnson
Jan 28, 2025
Maintains: Equal-Weight
Price Target: $159 → $166
Current: $167.28
Upside: -0.77%
Abbott Laboratories
Jan 27, 2025
Maintains: Overweight
Price Target: $149 → $158
Current: $140.22
Upside: +12.68%
Jan 22, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $12.27
Upside: +71.15%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $7.17
Upside: +206.83%
Jan 2, 2025
Initiates: Overweight
Price Target: $16
Current: $4.10
Upside: +290.24%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $94.30
Upside: +15.59%
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $220 → $234
Current: $272.64
Upside: -14.17%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $138 → $113
Current: $85.99
Upside: +31.41%
Jul 23, 2024
Maintains: Overweight
Price Target: $490 → $510
Current: $566.98
Upside: -10.05%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $13.49
Upside: +18.61%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $57 → $61
Current: $41.72
Upside: +46.21%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $15.86
Upside: +13.49%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $94.14
Upside: +1.98%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $70.81
Upside: +41.22%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $175.09
Upside: +138.73%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $11.68
Upside: +139.73%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $15.99
Upside: +319.01%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $9.33
Upside: +5,044.69%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $22.45
Upside: +287.61%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $5.41
Upside: +362.11%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $8.30
Upside: +8.43%